Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 239 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR A Subgroup of Patients with a Very Poor Prognosis Diffuse Intrinsic Pontine Glioma Linked to TP53 Alterations A Single Colonoscopy Reduces CRC Risk, but Not CRC Mortality EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab MOST POPULAR Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients... January 22, 2025 More Immunotherapy Options Approved for Treating Endometrial Cancer August 6, 2024 Immune Checkpoint Inhibitor-Based Systemic Therapy Combinations for Patients with HCC Amenable... January 15, 2025 ESMO Welcomes EU Proposals for MFF & FP10 and Calls for... July 21, 2025 Load more HOT NEWS 2022 ASCO Annual Meeting: Social Services Spending and Cancer Survival, Clinical... ESMO Welcomes EU Proposals for MFF & FP10 and Calls for... FDA Approves Pembrolizumab for Advanced Oesophageal or Gastro-Oesophageal Carcinoma The Appraisal – Does a charity have a role in biotech...
